Jupiter Neurosciences (JUNS) announced a strategic partnership with Zina Biopharmaceuticals to support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s disease. Under the terms of the agreement, Zina will provide comprehensive services related to the execution of the exploratory Phase 2a trial evaluating JOTROL, Jupiter’s patented resveratrol-based therapeutic platform. The primary objective of the trial will be to evaluate the safety and tolerability of JOTROL in patients with Parkinson’s, with secondary and exploratory endpoints to assess pharmacokinetics/pharmacodynamics of the drug.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JUNS:
- Jupiter Neurosciences Inc trading resumes
- Jupiter Neurosciences Inc trading halted, volatility trading pause
- Jupiter Neurosciences announces focus on NLRP3 pathway in JOTROL trials
- Jupiter Neurosciences jumps 19%, halts, after Greenridge starts at Buy
- Jupiter Neurosciences initiated with a Buy at Greenridge